593937 Disclosed is the use of 4-{ [3-(4-cyclohexylpiperazin-1-yI)-6-oxo-6H-anthra[1,9-cd]isoxazoI-5-yl]amino} benzoic acid or N-[(4-{ [3-(4-cyclohexylpiperazin-1-yl)-6-oxo-6H-anthra[1,9-cd]isoxazol-5-yl]amino} phenyl)sulfonyl]acetamide or a salt, solvate, ester, or prodrug thereof, in the manufacture of a medicament for the treatment in a patient of: (a) a pain selected from the group consisting of: acute pain, chronic pain, inflammatory pain, neuropathic pain, tonic pain, persistent pain, postoperative pain, chemical induced pain, chemotherapy-induced pain, cancer-pain, drug-induced pain, bone pain, pain associated with alcohol-induced hyperalgesia, and a combination thereof, and/or (b) skeletal muscle spasms, convulsive seizures, epilepsy, restenosis, atherosclerosis, psoriasis, thrombosis, burn, posttraumatic stress disorder, cardiac disorder, smoking cessation, inflammation, immune-mediated disorders, and a combination thereof and/or (c) a cancer selected from the group consisting of: brain, melanoma, multiple myeloma, squamous cell, bladder, gastric, pancreatic, breast, head, neck, esophageal, prostate, colorectal, lung, renal, ovarian, gynecological, thyroid, liver, and certain types of hematological malignancies, and a combination thereof and/or (d) causalgia, diabetes, collagen vascular disease, trigeminal neuralgia, spinal cord injury, brain stem injury, thalamic pain syndrome, complex regional pain syndrome type I/reflex sympathetic dystrophy, Fabry&rsquos syndrome, small fiber neuropathy, cancer, cancer chemotherapy, chronic alcoholism, stroke, abscess, demyelinating disease, viral infection, AIDS, burn, sunburn, arthritis, colitis, carditis, dermatitis, myositis, neuritis, mucositis, urethritis, cystitis, gastritis, pneumonitis, collagen vascular disease, trauma, maladaptive substance use, substance dependence, alcohol use or abuse, substance use or abuse, drug use or abuse, metastasis, fibromyalgia, irritable bowel syndrome, a temporomandibular disorde
